4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1,2,4)triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies
申请人:Merck Patent GmbH
公开号:US07485639B2
公开(公告)日:2009-02-03
Triazine derivatives of the formula (I) and physiologically acceptable salts and solvates thereof, in which R1, R2, A and R5 are as defined in Claim 1, exhibit phosphodiesterase IV inhibition and can be employed for the treatment of allergic diseases, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, autoimmune diseases, such as, for example, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumour growth or tumour metastases, sepsis, memory disorders, atherosclerosis and AIDS, furthermore for inhibiting the formation of TNFα.
式(I)的三嗪衍生物及其生理上可接受的盐和溶剂化物,其中R1,R2,A和R5如权利要求1所定义,表现出磷酸二酯酶IV抑制作用,并可用于治疗过敏性疾病、哮喘、慢性支气管炎、特应性皮炎、银屑病和其他皮肤疾病、炎症性疾病、自身免疫性疾病,例如类风湿性关节炎、多发性硬化症、克罗恩病、糖尿病或溃疡性结肠炎、骨质疏松、移植排斥反应、消瘦症、肿瘤生长或转移、败血症、记忆障碍、动脉粥样硬化和艾滋病,此外还可用于抑制TNFα的形成。